Discovery of imrecoxib

Chinese Journal of New Drugs

Volumn 21, Issue 3, 2012, Pages 223-230

  Guo, Zong Ru ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

COX 2 inhibitor; Imrecoxib; Moderate inhibition; New drug; Osteoarthritis; Pharmacophore based drug design

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; IMRECOXIB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; IN VIVO STUDY; OSTEOARTHRITIS; PHARMACOPHORE;

EID: 84859960197     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. XIE WL, CHIPMAN JG, ROBERTSON DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing [J]. Proc Natl Acad Sci USA, 1991, 88(7): 2692-2696.
2. VANE JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs [J]. Nat New Biol, 1971, 231(25): 232-235.
3. PENNING TD, TALLEY JJ, BERTENSHAW SR, et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib) [J]. J Med Chem, 1997, 40(9): 1347-1365.
4. PRASIT P, WANG C, BRIDEAU C, et al. The discovery of rofecoxib, [MK 966, VIOXX, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor [J]. Bioorg Med Chem Lett, 1999, 9(13): 1773-1778.
5. FRIESEN RW, BRIDEAN C, CHAN CC, et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors [J]. Bioorg Med Chem Lett, 1998, 8(19): 2777-2782.
6. TALLEY JJ, BROWN DL, CARTER JS, et al. 4-[5-Methyl-3-phenylisoxazol] 4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2 [J]. J Med Chem, 2000, 43(5): 775-777.
7. 1999, 9(2): 114-120.
8. 1999, 34(8): 590-595.
9. BAI AP, GUO ZR, HU WH, et al. Design, Synthesis and in vitro evaluation of a new class of novel cyclooxygenase-2 inhibitors: 3, 4-diaryl-3-pyrrolin-2-ones [J]. Chin Chem Lett, 2001, 12(9): 775-778.
10. SHEN F, BAI AP, GUO ZR, et al. Inhibitory effect of 3, 4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine reritoneal macrophages [J]. Acta Pharmacol Sin, 2002, 23(8): 762-768.
11. MCADAM BF, CATELLA-LAWSON F, MAEDINI IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 [J]. Proc Natl Acad Sci USA, 1999, 96(1): 272-277.
12. FITZGERALD GA, PATRONO C. The coxibs, selective inhibitors of cyclooxygenase-2 [J]. New Engl J Med, 2001, 345(6): 433-442.
13. 2005, 40(11): 967-969.
14. CHEN XH, BAI JY, SHEN F, et al. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect [J]. Acta Pharmacol Sin, 2004, 25(7): 927-931.
15. LI Q, HUANG HH, DONG Y, et al. Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs [J]. Acta Pharm Sin, 2005, 40(10): 912-915.
16. 102206178 [P]. 2011-10-05.
17. XU HY, XIE ZX, ZHANG P, et al. Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib [J]. Acta Pharmacol Sin, 2006, 27(3): 372-380.
18. XU HY, ZHANG Y, SUN Y, et al. Metabolism and excretion of imrecoxib in rat [J]. Xenobiotica, 2006, 36(5): 441-455.
19. XU HY, ZHANG P, GONG AS, et al. Formation of 4'-carboxyl acid metabolite of imrecoxib by rat liver [J]. Microsomes, 2006, 27(4): 506-512.
20. FENG ZQ, CHU FM, GUO ZR. Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib [J]. Bioorg Med Chem lett, 2009, 19(8): 2270-2272.